Cargando…

Pharmacogenomics of Cisplatin Sensitivity in Non-small Cell Lung Cancer

Cisplatin, a platinum-based chemotherapeutic drug, has been used for over 30 years in a wide variety of cancers with varying degrees of success. In particular, cisplatin has been used to treat late stage non-small cell lung cancer (NSCLC) as the standard of care. However, therapeutic outcomes vary f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rose, Maimon C., Kostyanovskaya, Elina, Huang, R. Stephanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411417/ https://www.ncbi.nlm.nih.gov/pubmed/25449594 http://dx.doi.org/10.1016/j.gpb.2014.10.003

Ejemplares similares

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
por: Delaney, Christopher, et al.
Publicado: (2015)

Pharmacogenomic Approach to Identify Drug Sensitivity in Small-Cell Lung Cancer
por: Wildey, Gary, et al.
Publicado: (2014)

The Use of Pharmacogenomics for Selection of Therapy in Non-Small-Cell Lung Cancer
por: Karim, Nagla A, et al.
Publicado: (2014)

Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective
por: Jiang, Wenxiao, et al.
Publicado: (2018)

Metformin enhances the radiosensitizing effect of cisplatin in non-small cell lung cancer cell lines with different cisplatin sensitivities
por: Riaz, Muhammad Assad, et al.
Publicado: (2019)

Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer
por: Szlosarek, Peter W., et al.
Publicado: (2021)

Emodin enhances cisplatin sensitivity in non-small cell lung cancer through Pgp downregulation
por: Peng, Shuai, et al.
Publicado: (2021)

Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
por: Li, Amin, et al.
Publicado: (2020)

Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
por: Stathopoulos, G. P., et al.
Publicado: (2011)

Demethoxycurcumin increases the sensitivity of cisplatin-resistant non-small lung cancer cells to cisplatin and induces apoptosis by activating the caspase signaling pathway
por: Chen, Yun, et al.
Publicado: (2020)

Synergistic effects of olaparib combined with ERCC1 on the sensitivity of cisplatin in non-small cell lung cancer
por: Xie, Kejie, et al.
Publicado: (2021)

MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin
por: Li, Weili, et al.
Publicado: (2016)

MicroRNA-608 sensitizes non-small cell lung cancer cells to cisplatin by targeting TEAD2
por: Wang, Yanli, et al.
Publicado: (2019)

The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer
por: Schettino, Clorinda, et al.
Publicado: (2008)

Comparison of Vinorelbine-Cisplatin with Gemcitabine-Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer
por: Ozkaya, Sevket, et al.
Publicado: (2008)

MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas
por: Fadejeva, Irina, et al.
Publicado: (2017)

Curcumin Increased the Sensitivity of Non-Small-Cell Lung Cancer to Cisplatin through the Endoplasmic Reticulum Stress Pathway
por: Wang, Lile, et al.
Publicado: (2022)

Prominin 2 decreases cisplatin sensitivity in non-small cell lung cancer and is modulated by CTCC binding factor
por: Tang, Jiyang, et al.
Publicado: (2023)

Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing
por: Hattinger, Claudia Maria, et al.
Publicado: (2022)

Astragaloside IV sensitizes non-small cell lung cancer cells to cisplatin by suppressing endoplasmic reticulum stress and autophagy
por: Lai, Song-Tao, et al.
Publicado: (2020)

Bag-1 Silence Sensitizes Non-Small Cell Lung Cancer Cells To Cisplatin Through Multiple Gene Pathways
por: Lv, Jiling, et al.
Publicado: (2019)

Lentinan combined with cisplatin for the treatment of non-small cell lung cancer
por: Zhao, Chenchen, et al.
Publicado: (2021)

Tumor Heterogeneity Underlies Differential Cisplatin Sensitivity in Mouse Models of Small-Cell Lung Cancer
por: Böttger, Franziska, et al.
Publicado: (2019)

MicroRNAs as Predictors of Lung-Cancer Resistance and Sensitivity to Cisplatin
por: Konoshenko, Maria, et al.
Publicado: (2022)

Dexamethasone Reduces Sensitivity to Cisplatin by Blunting p53-Dependent Cellular Senescence in Non-Small Cell Lung Cancer
por: Ge, Haiyan, et al.
Publicado: (2012)

mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9
por: Liu, Bo, et al.
Publicado: (2021)

AMIGO2 attenuates innate cisplatin sensitivity by suppression of GSDME‐conferred pyroptosis in non‐small cell lung cancer
por: Chen, Lian‐kuai, et al.
Publicado: (2023)

Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549)
por: Bian, Hai-Bo, et al.
Publicado: (2011)

Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer
por: Xiao, Lu, et al.
Publicado: (2017)

Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer
por: Ding, Qian, et al.
Publicado: (2013)

EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations
por: Gao, Jing, et al.
Publicado: (2016)

Propofol Improves Sensitivity of Lung Cancer Cells to Cisplatin and Its Mechanism
por: Huang, Yunfeng, et al.
Publicado: (2020)

Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment
por: Gao, Yanyun, et al.
Publicado: (2019)

Modulation of NF-κB/miR-21/PTEN Pathway Sensitizes Non-Small Cell Lung Cancer to Cisplatin
por: Yang, Zhenhua, et al.
Publicado: (2015)

Tumor suppressor miR-613 induces cisplatin sensitivity in non-small cell lung cancer cells by targeting GJA1
por: Luo, Jianhua, et al.
Publicado: (2021)

Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway
por: Dai, Yitian, et al.
Publicado: (2022)

Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
por: Yang, C H, et al.
Publicado: (2002)

Hsa_circ_0001946 Inhibits Lung Cancer Progression and Mediates Cisplatin Sensitivity in Non-small Cell Lung Cancer via the Nucleotide Excision Repair Signaling Pathway
por: Huang, Ma-Sha, et al.
Publicado: (2019)

DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer
por: Li, Man, et al.
Publicado: (2020)

Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer
por: Earle, C C, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_1m32nhrpm56pbemt7c1l25mv5i